Quick Takeaways
- TCG Crossover GP II, LLC filed SCHEDULE 13G for ADC Therapeutics SA Common Shares, par value CHF $0.08 per share (ADCT).
- Disclosed ownership: 9.2%.
- Date of event: 27 Oct 2025.
TCG Crossover GP II, LLC - 27 Oct 2025 SCHEDULE 13G Report for ADC Therapeutics SA Common Shares, par value CHF $0.08 per share (ADCT)
- Filing Manager
- TCG Crossover GP II, LLC
- Reporting Manager
- TCG Crossover GP II, LLC
- Symbol
- ADCT
- Shares outstanding
- 123,806,250 shares
- Disclosed Ownership
- 11,390,175 shares
- Ownership
- 9.2%
- Form type
- SCHEDULE 13G
- Filing time
- 17 Feb 2026, 16:26:45 UTC
- Date of event
- 27 Oct 2025
- SEC
- View on sec.gov
Quoteable Key Fact
"TCG Crossover GP II, LLC disclosed 9.2% ownership in ADC Therapeutics SA Common Shares, par value CHF $0.08 per share (ADCT) on 27 Oct 2025."
What Changed
- No earlier schedule filing is available for direct comparison.
- Current filing was accepted on 17 Feb 2026, 16:26.
Why This Matters
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Official SEC Source
Backed by Schedule 13D/13G
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
See Original FilingReporting Managers (3)
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| TCG Crossover GP II, LLC | 9.2% | 11,390,175 | 0 | 11,390,175 | /s/ Craig Skaling | Craig Skaling, Authorized Signatory | |
| TCG Crossover Fund II, L.P. | 9.2% | 11,390,175 | 0 | 11,390,175 | /s/ Craig Skaling | Craig Skaling, Authorized Signatory | |
| Chen Yu | 9.2% | 11,390,175 | 0 | 11,390,175 | /s/ Craig Skaling | Craig Skaling, as Attorney-in-Fact for Chen Yu |